Who is sponsoring NCT01738152?

NCT01738152 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT01738152 study?

NCT01738152 studies Breast Cancer, Endometrial Cancer.

What drugs are being tested in NCT01738152?

Interventions: HLA vaginal gel (HyaloGYN®),, questionnaires.

What is the status of NCT01738152?

NCT01738152 is currently COMPLETED.

Last reviewed 2021-07-22 · How we verify

A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health

NCT01738152 NA COMPLETED

The purpose of this study is to see whether it is feasible to conduct a study to determine if the use of hyaluronic acid (HLA) vaginal gel (HyaloGYN®) improves vulvovaginal health. This study aims to look at whether or not HyaloGYN® is effective in women with a history of hormone receptor positive cancer and experiencing vaginal and/or vulvar symptoms of estrogen deprivation following their breast and endometrial cancer treatment.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	NA
Status	COMPLETED
Enrolment	106
Start date	2012-11
Completion	2021-07-21

Conditions

Breast Cancer
Endometrial Cancer

Interventions

HLA vaginal gel (HyaloGYN®),
questionnaires

Primary outcomes

investigate feasibility of conducting a 12-week HLA treatment regimen — 12-week
a 12-week HLA treatment regimen, as defined by the percentage of women who are evaluable at the 12-week assessment (i.e., women who have completed both baseline and 12-week vaginal and vulvar outcome assessments).

Countries

United States